First-in-Human Phase 1 Study To Assess Safety, Tolerability, and Pharmacokinetics of a Novel Antifungal Drug, VL-2397, in Healthy Adults

抄録

<jats:p> VL-2397 is an antifungal drug with a novel mechanism of action, rapid fungicidal <jats:italic>in vitro</jats:italic> activity, and potent <jats:italic>in vivo</jats:italic> activity against <jats:named-content content-type="genus-species">Aspergillus fumigatus</jats:named-content> , including azole-resistant strains. VL2397-101, a phase 1 first-in-human, randomized, double-blind, placebo-controlled dose-escalation study, was conducted in healthy adults to determine the safety, tolerability, and pharmacokinetics (PK) of single and multiple ascending intravenous (i.v.) doses of VL-2397. </jats:p>

収録刊行物

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ